Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | SVP, Technical Operations | April 24, 2018 | April 25, 2018 |
| Immunovant, Inc.IMVT · Entity 3632 | Chief Technology Officer | October 07, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date April 24, 2018 · Filed April 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,646 |
Reported balance
After 2018-04-24 transaction · row 1
1 source rowRow 1 · 2018-04-24 · Sale · Disposed 4,854 · Balance 185,646 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant.
Immunovant, Inc.
Report date October 07, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 201,532 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-07 · Sale · Disposed 2,213 · Balance 203,128 F1: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Row 2 · 2026-10-07 · Sale · Disposed 1,596 · Balance 201,532 F3: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,437 of these RSUs vested on October 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,437 of these RSUs vested on October 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 9, 2026 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,596 | $32.06 | $51,167.76 |
DisclosureSEC source: 0001702969-26-000012 · wk-form4_1791579957.xml · nonDerivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,532 F3 · shares: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,437 of these RSUs vested on October 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 07, 2026 Filed Oct 9, 2026 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,213 | $32.06 | $70,948.78 |
DisclosureSEC source: 0001702969-26-000012 · wk-form4_1791579957.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,128 F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 23, 2026 Filed Jul 24, 2026 21:57 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,857 | $38.69 | $110,537.33 |
DisclosureSEC source: 0001702969-26-000010 · wk-form4_1784930232.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,341 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 77 | $39.99 | $3,079.23 |
DisclosureSEC source: 0001764013-26-000081 · wk-form4_1783714376.xml · nonDerivative · entry 4 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,198 F4 · shares: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,399 | $39.53 | $55,302.47 |
DisclosureSEC source: 0001764013-26-000081 · wk-form4_1783714376.xml · nonDerivative · entry 3 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,275 F4 · shares: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 105 | $39.99 | $4,198.95 |
DisclosureSEC source: 0001764013-26-000081 · wk-form4_1783714376.xml · nonDerivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,674 F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,906 | $39.53 | $75,344.18 |
DisclosureSEC source: 0001764013-26-000081 · wk-form4_1783714376.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,779 F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:45 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 6,723 | $38.94 | $261,793.62 |
DisclosureSEC source: 0001764013-26-000074 · wk-form4_1782517552.xml · nonDerivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,685 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.76 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:45 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 33,277 | $38.18 | $1,270,515.86 |
DisclosureSEC source: 0001764013-26-000074 · wk-form4_1782517552.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,408 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.74 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,754 | $29.62 | $81,573.48 |
DisclosureSEC source: 0001764013-26-000055 · wk-form4_1777061153.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,685 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on April 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,518 | $24.83 | $37,691.94 |
DisclosureSEC source: 0001702969-26-000006 · wk-form4_1775851354.xml · nonDerivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,439 F3 · shares: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on April 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 8,614 | $24.83 | $213,885.62 |
DisclosureSEC source: 0001702969-26-000006 · wk-form4_1775851354.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,957 F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 19,045 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:19 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 96,851 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001764013-26-000038 · wk-form4_1775765943.xml · derivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,851 Underlying: Common Stock · 96,851 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:19 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 66,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-26-000038 · wk-form4_1775765943.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,571 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:21 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,977 | $26.03 | $51,461.31 |
DisclosureSEC source: 0001702969-26-000002 · wk-form4_1769203286.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,634 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on January 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 55 | $26.92 | $1,480.60 |
DisclosureSEC source: 0001764013-26-000002 · wk-form4_1767992586.xml · nonDerivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,611 F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on January 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.91 - $26.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,148 | $26.51 | $30,433.48 |
DisclosureSEC source: 0001764013-26-000002 · wk-form4_1767992586.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,666 F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on January 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.90 - $26.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 20:36 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,520 | $19.03 | $47,955.60 |
DisclosureSEC source: 0001764013-25-000143 · wk-form4_1761338213.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,814 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on October 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 - $19.23 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 20:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,585 | $16.30 | $25,835.50 |
DisclosureSEC source: 0001764013-25-000138 · wk-form4_1760126514.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,334 F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on October 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.06 - $16.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 23, 2025 Filed Jul 25, 2025 21:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,805 | $18.15 | $50,910.75 |
DisclosureSEC source: 0001764013-25-000115 · wk-form4_1753477896.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,919 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:13 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,519 | $17.24 | $26,187.56 |
DisclosureSEC source: 0001764013-25-000108 · wk-form4_1752264819.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,724 F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 20:17 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,925 | $14.79 | $28,470.75 |
DisclosureSEC source: 0001764013-25-000083 · wk-form4_1745612230.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,243 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on April 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 20:08 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 5,004 | $12.99 | $65,001.96 |
DisclosureSEC source: 0001764013-25-000069 · wk-form4_1744402102.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,168 F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 13,744 of these RSUs vested on April 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:51 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 107,297 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000055 · wk-form4_1743713507.xml · derivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,297 Underlying: Common Stock · 107,297 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:51 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 76,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000055 · wk-form4_1743713507.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,172 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:23 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,195 | $23.59 | $51,780.05 |
DisclosureSEC source: 0001764013-25-000019 · wk-form4_1737753791.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,991 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on January 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| October 23, 2024 Filed Oct 25, 2024 20:21 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,740 | $29.53 | $80,912.20 |
DisclosureSEC source: 0001764013-24-000178 · wk-form4_1729887693.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,186 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on October 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 20:20 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,813 | $27.76 | $78,088.88 |
DisclosureSEC source: 0001764013-24-000143 · wk-form4_1722025247.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,926 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.37 - $28.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 21:20 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 7,239 | $28.90 | $209,207.10 |
DisclosureSEC source: 0001764013-24-000087 · wk-form4_1714166431.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,739 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 25,000 of these RSUs vested on April 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 68,723 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001764013-24-000057 · wk-form4_1712263135.xml · derivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,723 Underlying: Common Stock · 68,723 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 54,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000057 · wk-form4_1712263135.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,978 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:23 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001764013-23-000057 · wf-form4_168193578398335.xml · derivative · entry 2 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-04-17 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 17, 2024 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:23 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-23-000057 · wf-form4_168193578398335.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on April 17, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| April 24, 2018 Filed Apr 25, 2018 18:10 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 4,854 | $1.55 | $7,523.70 |
DisclosureSEC source: 0001209191-18-026137 · doc4.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,646 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:09 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 74,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067107 · doc4.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,500 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20,2021. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 20:17 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056567 · doc4.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,000 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 50% of the shares vest on each of October 6, 2018 and October 6, 2019. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 19:06 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $21.30 | $0.00 |
DisclosureSEC source: 0001209191-17-025827 · doc4.xml · derivative · entry 2 Stout Jay S · CIK 0001702969 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-04-02 F2 · derivative.exercise_date: 25% of the shares subject to the option become exercisable on April 3, 2018 and 1/48 of the shares subject to the option become exercisable monthly thereafter Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 19:06 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-025827 · doc4.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares subject to the Restricted Stock Units vest on each of April 3, 2018, April 3, 2019, April 3, 2020 and April 3, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.